Table 2

Toxicity and antileukemic activity of DX-8951f in the early-disease model

Dose totalaDaily (mg/kg)No. of miceToxic deathsLeukemic deathsMedian survivalb Days (range)Paraplegia
1-day
2020100 /1010 /1041 (29–66)8
404050 /55 /549 (39–102)3
505052 /53 /552 (14–79)1
606050 /55 /568 (53–103)1
808050 /55 /554 (49–81)0
3-day
103.350 /55 /545 (36–72)3
15550 /55 /564 (57–72)1
206.5100 /1010 /1050 (35–72)5
301054 /51 /5NE0
4013.351 /53 /5111 (14–128+)d0
8026.554 /51 /5NEc0
5-day
7.51.5101 /109 /1057 (16–60)4
102101 /109 /1054 (17–89)3
15353 /52 /5NE0
20453 /52 /5NE0
801655 /5NENE0
  • a The dose of DX-8951f is expressed as an anhydrous free base.

  • b Kaplan-Meier estimates for median survival.

  • c NE, not evaluable secondary to excessive toxicity.

  • d One mouse sacrificed free of disease on day 128.